Objective To establish a drug use evaluation(DUE)criteria for alteplase in the treatment of acute ischemic stroke(AIS),and to evaluate the use of the drug by weighted TOPSIS method,to provide a reference for rational use of alteplase.Methods Based on the drug package insert,relevant guidelines,the DUE criteria for alteplase in the treatment of AIS were developed combined with expert consultation.The weighted TOPSIS method was used to evaluate the rationality of alteplase use in inpatients with AIS in the People's Hospital of Guangxi Zhuang Autonomous Region from January 2020 to June 2022,based on the attribute hierarchy model.Results A total of 126 medical records were included.Among them,80 cases(63.49％)exhibited a high degree of adherence(C,＞0.8)between the prescribed drug regimens and the optimal recommendations,which was considered reasonable.Additionally,40 cases(31.75％)fell within the range of 0.6 ≤ Ci ≤ 0.8,indicating a basic reasonable adherence,and 6 cases(4.76％)had a C,＜0.6,suggesting an unreasonable level of adherence.The irrational use of the drug mainly involved contraindications(32.54％),dosage(7.14％),and drug conversion(7.14％),among other aspects.Conclusion The weighted TOPSIS method is used to evaluate the rationality of alteplase in the treatment of acute ischemic stroke(AIS),and the results are intuitive and comprehensive.There are still problems in the use of alteplase in this hospital,and it is necessary to strengthen intervention to promote rational clinical use of alteplase in terms of contraindication of medication and dosage,etc.

Objective To understand occurrence of bleeding related to drug interactions in patients who received combined treatment with warfarin and other drugs in Department of Cardiovascular Medicine and investigate control measures.Methods The data of inpatients using warfarin in the Department of Cardiovascular Medicine,Peking University First Hospital from January 2012 to June 2013 were collected and analyzed retrospectively.The conditions of concomitant drugs and occurrence of bleeding possibly caused by drug interactions were recorded and the drugs which were commonly used in the Department were screened.Results A total of 141 patients were enrolled including 90 men aged from 21 to 83 years with an average age of (63 ± 13) years and 51 women aged from 43 to 85 years with an average age of (65 ± 11)years.Most protopathy was atrial fibrillation which accounted for 79.4％ (112 cases).Of the 141 patients,there were 14 cases (9.9％) of slight bleeding possibly because of drug interactions including 5 cases of stool occult blood,3 cases of dermal ecchymosis and 1 case had each of the following:operative wound bleeding,oral mucosal bleeding and blood in phlegm,colporrhagia,epistaxis,hematuresis,and gum bleeding.The occurrence of bleeding in the 14 patients involved totally 9 kinds of drugs containing low molecular weight heparin (related to 9 cases),atorvastatin (related to 6 cases),amiodarone (related to 4 cases),acarbose (related to 3 cases),aspirin (related to 4 cases),propafenone (related to 3 cases),omeprazole (related to 2 cases),clopidogrel (related to 2 cases),and moxifloxacin (related to 1 case) and,of them,the highest occurrence was due to low molecular weight heparin,which accounted for 64.2％.In the 9 kinds of drugs in the 141 patients,low molecular weight heparin had the highest concomitant frequency combined with warfarin accounted for 73.1％ (103/141) and moxifloxacin had the highest bleeding incidence accounted of 1/5.Conclusions Bleeding may be caused by drug reactions due to combination therapy with warfarin and parts of clinical common cardiovascular drugs.Positive clinical pharmaceutical care of warfarin will be of great importance in prevention of bleeding.

Objective To understand occurrence of bleeding related to drug interactions in patients who received combined treatment with warfarin and other drugs in Department of Cardiovascular Medicine and investigate control measures.Methods The data of inpatients using warfarin in the Department of Cardiovascular Medicine,Peking University First Hospital from January 2012 to June 2013 were collected and analyzed retrospectively.The conditions of concomitant drugs and occurrence of bleeding possibly caused by drug interactions were recorded and the drugs which were commonly used in the Department were screened.Results A total of 141 patients were enrolled including 90 men aged from 21 to 83 years with an average age of (63 ± 13) years and 51 women aged from 43 to 85 years with an average age of (65 ± 11)years.Most protopathy was atrial fibrillation which accounted for 79.4％ (112 cases).Of the 141 patients,there were 14 cases (9.9％) of slight bleeding possibly because of drug interactions including 5 cases of stool occult blood,3 cases of dermal ecchymosis and 1 case had each of the following:operative wound bleeding,oral mucosal bleeding and blood in phlegm,colporrhagia,epistaxis,hematuresis,and gum bleeding.The occurrence of bleeding in the 14 patients involved totally 9 kinds of drugs containing low molecular weight heparin (related to 9 cases),atorvastatin (related to 6 cases),amiodarone (related to 4 cases),acarbose (related to 3 cases),aspirin (related to 4 cases),propafenone (related to 3 cases),omeprazole (related to 2 cases),clopidogrel (related to 2 cases),and moxifloxacin (related to 1 case) and,of them,the highest occurrence was due to low molecular weight heparin,which accounted for 64.2％.In the 9 kinds of drugs in the 141 patients,low molecular weight heparin had the highest concomitant frequency combined with warfarin accounted for 73.1％ (103/141) and moxifloxacin had the highest bleeding incidence accounted of 1/5.Conclusions Bleeding may be caused by drug reactions due to combination therapy with warfarin and parts of clinical common cardiovascular drugs.Positive clinical pharmaceutical care of warfarin will be of great importance in prevention of bleeding.